Table 3.
The marginal cost-effectiveness and cost-benefit of SSF in Vancouver using Jacobs et al.’s [30] model
| Variables | Annual cost of operation ($) | Sharing rate (%) | # of HCV averted | Cost-effectiveness ratio HCV ($) | Cost-benefit ratio HCV |
|---|---|---|---|---|---|
| Post SSF | 97,203 | 69 | 57 | 1,705 | 20.6 |
| (78, 60) | (65, 50) | (1,495, 1,944) | (23.5, 18.1) | ||
| Two SSF | 97,203 | 59 | 52 | 3,739 | 18.8 |
| (67, 52) | (56, 43) | (1,736, 2,261) | (20.2,15.5) | ||
| Three SSF | 97,203 | 58 | 1 | 97,203 | 0.4 |
| (67, 52) | (1, 1) | (97,203, 97,203) | (0.4, 0.4) | ||
| Four SSF | 97,203 | 58 | 1 | 97,203 | 0.4 |
| (67, 52) | (1, 0.5) | (97,203, 194,406) | (0.4, 0.2) | ||
| Five SSF | 97,203 | 58 | 1 | 97,203 | 0.4 |
| (67, 52) | (1, 0.5) | (97,203, 194,406) | (0.4, 0.2) | ||
| Six SSF | 97,203 | 57 | 1 | 97,203 | 0.4 |
| (66, 52) | (1, 0.5) | (97,203, 194,406) | (0.4, 0.2) | ||
| Seven SSF | 97,203 | 57 | 1 | 97,203 | 0.4 |
| (66, 52) | (1, 0.5) | (97,203, 194,406) | (0.4, 0.2) |
The numbers in parentheses represent the results of the sensitivity analysis (90% sharing rate, 70% sharing rate).